If you take a GLP-1 for weight, the question of Ozempic knee arthritis pain has probably never crossed your mind. It should. The STEP-9 trial, published in the New England Journal of Medicine, gives the strongest signal yet that semaglutide (the molecule in Ozempic and Wegovy) does more than shrink the scale. It eased knee pain, in a study that was overwhelmingly a study of women.
What happened
STEP-9 enrolled 407 adults with obesity and moderate knee osteoarthritis, randomly assigned to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Notably, 81.6% of participants were women.
The pain results were large. On the WOMAC pain scale (where higher means worse), the semaglutide group dropped 41.7 points from a baseline near 71, roughly a 59% improvement. Placebo dropped 27.5 points, about 39%. Body weight fell 13.7% on semaglutide versus 3.2% on placebo, and physical function improved more in the treated group too. Semaglutide is not approved by the FDA to treat osteoarthritis, and this was not designed to win that label. But as a relief signal, it is hard to ignore.
Is it the weight, or the medicine itself?
The obvious explanation is weight: lighter load on the joint, less pain. That is real, and it matters. Yet 2026 lab work published in Cell Metabolism, led by researchers at Washington University in St. Louis, complicates the tidy story. In mouse models and a small human pilot, semaglutide appeared to protect cartilage directly, reducing degeneration and bone-spur formation even when body weight did not change.
The proposed mechanism is metabolic: semaglutide seems to nudge cartilage cells (chondrocytes) away from inefficient fuel-burning toward a healthier energy pathway, calming the low-grade inflammation that wears a joint down. This fits a broader picture of how these medicines lower inflammatory signals across the body, a thread we follow in our explainers on GLP-1s and joint health and GLP-1s and inflammation. Early, animal-heavy, not proof. But a genuine lead.
What it means for you
Knee osteoarthritis is not gender-neutral. Women carry roughly 1.7 times the prevalence men do, often with more severe symptoms and a steeper hit to daily function, partly tied to anatomy and to hormonal shifts that our piece on GLP-1s in perimenopause touches on. So a pain signal in a trial that was 82% women is unusually relevant to you.
A few calm caveats. This is not a reason to start or stay on a GLP-1 for your knees alone. The benefit travels with the rest of the medicine, including the appetite drop that makes protein and strength training non-negotiable for protecting the muscle that stabilizes your joints. If your knees feel better, tell your prescriber; if they do not, that is worth a conversation too.
What Steady does with this
Pain and stiffness are easy to forget by your next appointment. Steady tracks 14 GLP-1 symptoms over time and turns a month into one clean page, so when your doctor asks how your joints are doing, you have the pattern, not a guess.
